ZMPSTE24 and cardiomyopathy: However, one key difference is the model we used relied on mutating the site of ZMPSTE24 cleavage and, therefore, does not fully model the problem in HIV-associated cardiomyopathy, where a Zmpste24-KO or HIV PI pharmacological intervention would be interesting for further study.